OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	88
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	82
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	79
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	71
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	66
Theranostic strategies in sarcoma: preliminary clinical evidence	58
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	47
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	45
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	39
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	36
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	35
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	35
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	33
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	32
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	32
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	31
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	29
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	28
Emerging treatments for chronic urticaria	27
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	22
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	22
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	22